Comparative Pharmacology
Head-to-head clinical analysis: BUTALAN versus SODIUM PENTOBARBITAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTALAN versus SODIUM PENTOBARBITAL.
BUTALAN vs SODIUM PENTOBARBITAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Butalan is an ergot alkaloid derivative that acts as a partial agonist at serotonin (5-HT2B) receptors and an antagonist at alpha-adrenergic and dopamine (D2) receptors. It also inhibits prolactin secretion by stimulating dopamine receptors in the pituitary.
Barbiturate that enhances GABA-A receptor activity, prolonging chloride channel opening and increasing inhibitory neurotransmission. At high doses, it acts as a GABA mimetic and depresses neuronal excitability.
1-2 tablets (50-100 mg butalbital, 325-650 mg acetaminophen, 40 mg caffeine) orally every 4 hours as needed, not exceeding 6 tablets per day.
IV: 100-150 mg administered over 1-2 minutes for induction of anesthesia; for seizure control, 100 mg IV every 5-10 minutes up to 500 mg. For maintenance of anesthesia, 50 mg IV as needed every 15-30 minutes. IM: 150-200 mg for preoperative sedation.
None Documented
None Documented
4-6 hours (terminal); prolonged in renal impairment (up to 12-15 hours)
15-50 hours (dose-dependent; prolonged in hepatic impairment).
Primarily renal (70% unchanged, 20% as metabolites); fecal 10%
Renal (25-50% unchanged); hepatic metabolism to inactive metabolites; fecal <5%.
Category C
Category D/X
Barbiturate
Barbiturate